Table 1

Summary of patient characteristics by patient group

GroupAllP value
CtrlIBD
N (%)N (%)N (%)
Gender
 Female60 (40)18 (60)78 (43.33)0.07
 Male90 (60)12 (40)102 (56.67)
Race
 Black19 (12.67)1 (3.33)20 (11.11)0.31
 Caucasian128 (85.33)29 (96.67)157 (87.22)
 Multiracial3 (2)0 (0)3 (1.67)
Smoking status
 Former smoker83 (55.33)16 (53.33)99 (55)>0.99
 Never smoked tobacco43 (28.67)9 (30)52 (28.89)
 Smokes tobacco daily24 (16)5 (16.67)29 (16.11)
History of other autoimmune disorders
 No124 (82.67)23 (76.67)147 (81.67)0.44
 Yes26 (17.33)7 (23.33)33 (18.33)
Small bowel surgery
 No143 (95.33)21 (70)164 (91.11)0.0002
 Yes7 (4.67)9 (30)16 (8.89)
Large bowel surgery
 No134 (89.33)16 (53.33)150 (83.33)<0.0001
 Yes16 (10.67)14 (46.67)30 (16.67)
Cancer stage
 26 (4)0 (0)6 (3.33)0.48
 312 (8)4 (13.33)16 (8.89)
 4132 (88)26 (86.67)158 (87.78)
Cancer type
 Cancer of bladder4 (2.67)2 (6.67)6 (3.33)0.95
 Cancer of breast6 (4)1 (3.33)7 (3.89)
 Cancer of bronchus; lung80 (53.33)15 (50)95 (52.78)
 Cancer of colon11 (7.33)2 (6.67)13 (7.22)
 Cancer of head and neck5 (3.33)1 (3.33)6 (3.33)
 Cancer of kidney and renal pelvis7 (4.67)2 (6.67)9 (5)
 Cancer of other urinary organs3 (2)1 (3.33)4 (2.22)
 Cancer of rectum and anus3 (2)1 (3.33)4 (2.22)
 Melanomas of skin24 (16)4 (13.33)28 (15.56)
 Melanoma of orbit7 (4.67)1 (3.33)8 (4.44)
Cancer treatment
 Atezolizumab22 (14.67)5 (16.67)27 (15)0.996
 Atezolizumab, followed by ipilimumab, nivolumab combination1 (0.67)0 (0)1 (0.56)
 Durvalumab5 (3.33)1 (3.33)6 (3.33)
 Ipilimumab, nivolumab combination17 (11.33)3 (10)20 (11.11)
 Ipilimumab, nivolumab combination, followed by pembrolizumab4 (2.67)1 (3.33)5 (2.78)
 Nivolumab36 (24)8 (26.67)44 (24.44)
 Pembrolizumab65 (43.33)12 (40)77 (42.78)
No of doses, N (median, range)6 (1–83)6 (1–42)6 (1–83)0.88
History of chemotherapy
 No52 (34.67)10 (33.33)62 (34.44)>0.99
 Yes98 (65.33)20 (66.67)118 (65.56)
History of radiation therapy
 No130 (86.67)27 (90)157 (87.22)0.77
 Yes20 (13.33)3 (10)23 (12.78)
Prior steroid use
 No19 (12.67)5 (16.67)24 (13.33)0.56
 Yes131 (87.33)25 (83.33)156 (86.67)
Age at treatment, years (median, range)67 (23–84)67 (39–81)67 (23–84)0.54
  • Patients with IBD and controls were propensity score matched by cancer type, cancer mediation, and age. P values by Fisher’s exact test. Summary of age and number of doses by patient group. P value by Wilcoxon rank-sum test.

  • IBD, inflammatory bowel disease.